Voyager Therapeutics Names Robin Swartz President, Expects Her To Succeed CEO Alfred Sandrock

The board's pick is expected to take over as CEO after initial safety data from an Alzheimer's gene therapy trial, with a $625,000 salary.

Share
Voyager Therapeutics Names Robin Swartz President, Expects Her To Succeed CEO Alfred Sandrock

Voyager Therapeutics' board appointed Robin Swartz president effective immediately on Tuesday, according to an 8-K filed Wednesday. The filing says she is also expected to succeed CEO Alfred Sandrock after the company receives initial acute safety data from its VY1706 trial in adults with early Alzheimer's disease.

What the 8-K says

Swartz was the company's chief business officer and chief operating officer when the board named her. The succession is described as expected, not completed: it follows the anticipated receipt of the safety data in the first quarter of 2027.

Sandrock, whose full name in the filing is Alfred W. Sandrock, Jr., M.D., Ph.D., is expected to stay on the board after the handover.

Swartz, 56, has been chief operating officer and chief business officer since November 2024, and principal financial officer and treasurer since May 2026. The filing says she began at Genzyme in 1995 and later held senior roles at Sanofi Genzyme before joining Voyager.

Pay and severance terms

Under an amended and restated employment agreement, Swartz gets a base salary of $625,000 and is eligible for an annual cash bonus targeted at 50% of salary.

The board also approved, effective November 1, 2026, a stock option on 318,500 shares and restricted stock units for 68,250 shares. The option runs ten years and vests monthly over four years, starting on October 20, 2026. The units vest in thirds over three years.

If she resigns for good reason or is fired without cause, she becomes eligible for 12 months of salary, a pro rata share of her target bonus and up to 12 months of COBRA health premiums. If that happens within 12 months after a sale of the company, all of her equity awards would also vest in full. Both packages depend on her signing a release of claims.

What to watch

The trigger is the initial acute safety data from the VY1706 trial, anticipated in the first quarter of 2027. Voyager shares closed at $2.19 on Tuesday, up about 7% on the session, before the filing appeared Wednesday.

Until that data arrives, Sandrock stays CEO and Swartz holds the president title.

Sources